Eyenovia (EYEN) provided an update on recent progress made in the development of the Company’s novel Optejet User Filled Device, UFD. The user-filled Optejet is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, spanning multiple billion-dollar markets. As of today, the Company has completed the following parameters: Physical requirements such as dimensions and weight, Usability requirements identified, Dosing performance, Longevity testing, Safety testing of the base according to recognized standards.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYEN:
- Eyenovia Delays Yearly Report Filing
- EYEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Eyenovia’s Strategic Position and Uncertain Prospects: Hold Rating Amid Merger and Growth Challenges
- Eyenovia enters non-binding LOI to effect reverse merger with Betaliq
- Eyenovia regains compliancce with Nasdaq Stock Market
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue